SpectraCure to the Premier Segment of First North Growth Market
SpectraCure AB (publ) announces today that Nasdaq has approved the Company's application to move its stock trading to First North Premier Growth Market. The transfer is an important step towards a future listing on Nasdaq Stockholm’s main market. The trade in SpectraCure’s shares on First North Premier Growth Market will be initiated on Thursday, October […]
Correction: Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
Correction concerning inaccurate reference under the EU Market Abuse Regulation (MAR). The pressrelease without reference is found below. Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used […]
Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used in SpectraCure's ongoing clinical study. The technology leads to increased precision, accuracy and safety in the treatment of recurrent prostate cancer. SpectraCure runs an EU-funded development project, together with MedCom GmbH. The purpose of the […]
SpectraCure presentations at investor meetings this fall
SpectraCure (http://www.spectcomracure.) will be presented at Småbolagsjakten Live, September 25th and at at Stora Aktiedagen, November 4th. SpectraCure will be presented at Småbolagsjakten Live, September 25th Welcome to come and listen when the CEO of SpectraCure, Masoud Khayyami, holds a company presentation at the investor meeting Småbolagsjakten Live.The event has attracted great interest and is already sold […]
SpectraCure strengthens the organization with a PR Manager
September 1st, 2019 Annika Andersson will start as PR Manager at SpectraCure. Annika has a long experience of public relations, media and communication both strategically and operationally and has for the past 16 years run a communication agency. Annika contributes with expertise, experience and commitment. – The new role is also an important strengthening to […]
SpectraCure AB Quarterly report (1 April to 30 June) 2019
Second quarter (1 April – 30 June 2019) Net sales for the quarter amounted to TSEK 0 (0). Other income amounted to TSEK 663 (406). Profit after tax amounted to TSEK -4 149 (-4 028). Corresponding to SEK -0,05 (-0,07) per share. Operating cash flow was TSEK -3 547 (-2 977). Cash as of 30 […]
SpectraCures new generation P18
SpectraCure’s current main focus are the clinical phase 2 study and the development of the new generation of SpectraCure's treatment system. The clinical trial, designated for treatment of patients with recurrent prostate cancer using the company's photodynamic therapy (PDT) technology, is ongoing at our partner hospitals. The recruitment of patients for the fall in the […]
Great attention for SpectraCure in Boston
SpectraCure received a lot of attention around its clinical study results at the World Conference in Boston, attended by world leading clinical researchers. On Wednesday, July 3rd, SpectraCure presented results from the company's phase 1 study at the 17th International Photodynamic Association World Congress in Boston, USA. Johannes Swartling, CTO of SpectraCure held the presentation […]
SpectraCure reports positive results from the company’s clinical phase 1-study
Today July 2nd, 2019, SpectraCure AB ("Spec") reports positive results and good clinical effects regarding safety in the company's clinical phase 1-study of patients with recurrent prostate cancer. SpectraCure has conducted a clinical phase 1-study on treatment of patients with recurrent prostate cancer with the company's photodynamic therapy (PDT) technology. A total of 11 patients […]
SpectraCure presents results from Phase 1 study
SpectraCure presents results from the company's Phase 1 study at The 17th International Photodynamic Association World Congress in Boston. SpectraCure (publ) will present results from the company's Phase 1 study at the International Photodynamic Association World Congress arranged June 28th – July 4th in Boston, Massachusetts, USA. The presentation will be held by Johannes Swartling, […]
